PharmaResearch파마리서치
214450 · KOSDAQ · ₩214450 · 파마리서치
₩228,500▼ ₩3,000 (1.30%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 77.7% | 76.7% | 71.8% | 72.9% | 72.7% | 70.3% |
| Operating margin | 39.4% | 40.0% | 36.0% | 35.3% | 33.8% | 34.1% |
| Net margin | 30.8% | 30.8% | 26.3% | 29.3% | 20.8% | 30.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +12.5% | +53.2% | +34.1% | +34.0% | +26.4% | — |
| Operating income growth | +10.8% | +70.1% | +36.6% | +40.0% | +25.6% | — |
| Net income growth | +12.5% | +79.4% | +20.2% | +88.7% | −13.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 25.7% | 26.9% | 18.9% | 19.7% | 12.5% | 15.3% |
| Return on assets | 17.0% | 17.7% | 12.8% | 15.2% | 9.6% | 10.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 40.3% | 44.2% | 50.3% | 15.8% | 28.6% | 30.2% |
| Net debt to equity | −27.1% | −23.1% | −27.2% | −14.4% | −3.5% | 4.9% |
| Current ratio | 772.5% | 687.5% | 669.6% | 389.2% | 455.9% | 430.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: PharmaResearch / 파마리서치 / 214450 / KRX:214450
Source: KRX statistical information